Construction and expression of humanized chimeric T cell receptor specific for chronic myeloid leukemia cells

Biotechnology Letters

Volumn 34, Issue 7, 2012, Pages 1193-1201

  Wang, Dong ^a   Zhang, Lijun ^a   Li, Yajuan ^a   Wang, Haixia ^a   Xiao, Qing ^a   Cao, Weixi ^a   Feng, Wenli ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Adoptive immunotherapy; Chimeric T cell receptor; Chronic myeloid leukemia; Monoclonal antibody; scFv

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; CELL SURFACES; CHRONIC MYELOID LEUKEMIAS; GENES ENCODING; HEAVY AND LIGHT CHAINS; HUMAN T LYMPHOCYTES; HYBRIDOMA CELLS; RETROVIRAL VECTORS; SCFV; SIGNALING MOLECULES; SINGLE CHAIN VARIABLE FRAGMENTS; T CELL RECEPTOR; T LYMPHOCYTES; THERAPEUTIC AGENTS;

CELL CULTURE; CELL MEMBRANES; GENES; MONOCLONAL ANTIBODIES;

DISEASES;

LYMPHOCYTE ANTIGEN RECEPTOR; RECOMBINANT PROTEIN;

ADOPTIVE TRANSFER; ANIMAL; ARTICLE; CHRONIC MYELOID LEUKEMIA; GENE EXPRESSION; GENE VECTOR; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; MOUSE; RETROVIRUS;

ADOPTIVE TRANSFER; ANIMALS; GENE EXPRESSION; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT PROTEINS; RETROVIRIDAE;

MURINAE;

EID: 84862805725     PISSN: 01415492     EISSN: 15736776     Source Type: Journal    
DOI: 10.1007/s10529-012-0896-5     Document Type: Article

References (16)

1. Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA (2003) Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 26(4): 332-342.
2. Eshhar Z, Waks T, Gross G, Schindler DG (1993) Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 90(2): 720-724.
3. Friedmann-Morvinski D, Bendavid A, Waks T, Schindler D, Eshhar Z (2005) Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation. Blood 105(8): 3087-3093.
4. Guilhot F, Roy L, Saulnier PJ, Guilhot J, Barra A, Gombert JM, Turhan A (2008) Immunotherapeutic approaches in chronic myelogenous leukemia. Leuk Lymphoma 49(4): 629-634.
5. Ho WY, Blattman JN, Dossett ML, Yee C, Greenberg PD (2003) Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell 3(5): 431-437.
6. Hombach A, Wieczarkowiecz A, Marquardt T, Heuser C, Usai L, Pohl C, Seliger B, Abken H (2001) Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. J Immunol 167(11): 6123-6131.
7. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M (2002) Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol 20(1): 70-75.
8. Mapara MY, Sykes M (2004) Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 22(6): 1136-1151.
9. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S (2000) Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74: 181-273.
10. Power BE, Caine JM, Burns JE, Shapira DR, Hattarki MK, Tahtis K, Lee FT, Smyth FE, Scott AM, Kortt AA, Hudson PJ (2001) Construction, expression and characterisation of a single-chain diabody derived from a humanised anti-Lewis Y cancer targeting antibody using a heat-inducible bacterial secretion vector. Cancer Immunol Immunother 50(5): 241-250.
11. Rezvani K, Yong AS, Mielke S, Savani BN, Musse L, Superata J, Jafarpour B, Boss C, Barrett AJ (2008) Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 111(1): 236-242.
12. Rossig C, Brenner MK (2004) Genetic modification of T lymphocytes for adoptive immunotherapy. Mol Ther 10(1): 5-18.
13. Schmitt M, Li L, Giannopoulos K, Chen J, Brunner C, Barth T, Schmitt A, Wiesneth M, Dohner K, Dohner H, Greiner J (2006) Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules. Exp Hematol 34(12): 1709-1719.
14. Willemsen RA, Weijtens ME, Ronteltap C, Eshhar Z, Gratama JW, Chames P, Bolhuis RL (2000) Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR. Gene Ther 7(16): 1369-1377.
15. Yee C (2005) Adoptive T cell therapy: addressing challenges in cancer immunotherapy. J Transl Med 3(1): 17.
16. Yotnda P, Firat H, Garcia-Pons F, Garcia Z, Gourru G, Vernant JP, Lemonnier FA, Leblond V, Langlade-Demoyen P (1998) Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest 101(10): 2290-2296.